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Jaeken's syndromeycosylation are a clinically and genetically heterogeneous group of disorders
resulting from abnormal glycosylation of various glycoconjugates. The ﬁrst description of congenital
disorders of glycosylation was published in the early 80s and once screening tests for glycosylation disorders
(CDGs) became readily available, CDG-Ia became the most frequently diagnosed CDG subtype. CDG-Ia is pan-
ethnic and the spectrum of the clinical manifestations is still evolving: it spans from severe hydrops fetalis
and fetal loss to a (nearly) normal phenotype. However, the most common presentation in infancy is of a
multisystem disorder with central nervous system involvement.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionCongenital disorders of glycosylation (CDG) are a rapidly enlarging
group of (neuro)metabolic disorders. The ﬁrst patientswere described
by the Belgian paediatrician Professor Jaak Jaeken in 1980 [1] and it
took 15 years for the biochemical basis to be unravelled, and the
defective enzyme, phosphomannomutase (PMM) identiﬁed [2]. It was
then understood, that a deﬁciency of this cytosolic enzyme leads to an
early disruption of the N-glycan assembly of glycoproteins. Another
two years later, the gene was cloned and the diagnosis of so called
‘CDG-Ia’ (OMIM # 212065) could be conﬁrmed by mutational studies
[3]. Most of CDG subtypes including CDG-Ia are inherited as autosomal
recessives.
When CDG was ﬁrst described it was known as disialotransferrin
developmental deﬁciency or carbohydrate deﬁcient glycoprotein
syndrome or Jaeken's disease, clinicians looked out for patients
presenting with similar symptoms as originally described. This was a
combination of developmental delay, peculiar fat pads, cerebellar
hypoplasia and inverted nipples [4]. However, once a powerful
screening test (transferrin isoelectric focusing) was established in
1984 [5] and was applied on a broader population, it soon became
evident, that CDG-Ia is a multisystem disorder with a highly variable
phenotype.ital disorders of glycosylation;
; CDT, Carbohydrate-deﬁcient
GlcNAc, N-acetylglucosamine;
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ll rights reserved.2. Clinical description of CDG-Ia
CDG-Ia is by far the most common defect in the group of N-
glycosylation defects. It has been observed worldwide and several
countries have published CDG-Ia cohort studies [6–13].
CDG-Ia patients, are usually born after an uneventful pregnancy at
termwith a good birth weight, but are often symptomatic at birth and
therefore should be able to be diagnosed in the neonatal period. The
most predominant features of CDG-Ia babies are muscular hypotonia,
inverted nipples and unusual subcutaneous fat pads. The patients
might present with dysmorphic features such like large protruding
ears, high forehead, triangular face and thin upper lip. Although these
are very common symptoms, any or all of them can be missing.
It was thought that the course of patients with CDG-Ia will usually
progress through four stages: the infantile multisystemic stage, the
childhood ataxia-mental retardation stage, the teenage leg atrophy
stage and the adult hypogonadal stage [14]. This still applies to the
majority of CDG-Ia patients that survive the early years but the
mortality is as high as 20% in CDG-Ia patients with the so called
‘visceral’ form, presenting with a combination of neurological and
extraneurological manifestations; lethality is often attributed to
(multi) organ failure [12].
It is now realised that almost any organ system can be affected in
CDG-Ia patients and the combination and severity of the different
signs and symptoms can vary widely. Clinical variability is not only
seen in patients with the same PMM2 genotypes, but even between
affected siblings and monozygotic twins [15–18], suggesting an
additional impact of both environmental and other genetic factors.
3. Organ speciﬁc involvement
Table 1 summarises clinical signs and symptoms of CDG-Ia.
Table 1
Clinical features of CDG-Ia patients.
Neurology Axial hypotonia; peripheral neuropathy; hyporeﬂexia; developmental delay; seizures; stroke-like events; micro- and macrocephaly; myopathy
Gastroenterology/hepatology Failure to thrive; vomiting; protein-losing enteropathy; liver dysfunction; hepatomegaly; chronic diarrhoea
Neonatology Hydrops; ascites; pleural effusions; multiorgan failure; failure to thrive; ﬂoppy baby
Haematology Thrombocytopenia; coagulopathy; thrombosis; anaemia; leukocytosis
Endocrinology Hyperinsulinaemic hypoglycaemia; hypothyroidism; hypergonadotropic hypogonadism; growth retardation
Clinical genetics Mild dysmorphic facial features; inverted nipples
Orthopaedics Osteopenia; joint contractures; kyphosis/scoliosis; short limbs; arthrogryposis
Ophthalmology Abnormal eye movements; squint; cataract; retinitis pigmentosa; nystagmus; (transient) cortical blindness
Radiology Small cerebellum, olivopontocerebellar hypoplasia; delayed myelinisation
Histology Liver ﬁbrosis; liver cirrhosis; lamellar inclusions in hepatocytes; renal microcysts
Dermatology Abnormal fat distribution
Nephrology Nephrotic syndrome; tubulopathy; cystic kidneys, enlarged kidney
Immunology Recurrent infections; hypogammaglobulinaemia
Cardiology Cardiomyopathy; pericardial effusions, cardiac ischemia, cardiac tamponade
Biochemistry Hypoalbuminaemia; elevated transaminases; low cholesterol, triglycerides; decreased antithrombin III; decreased factor VIII, IX and XI;
decreased protein C and S; elevated FSH, LH and prolactin; low free T4, increased ferritinaemia
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Several reviews on the neurological presentation of CDG-Ia have
been published [19–21].
Psychomotor development is usually delayed in CDG-Ia patients
and this becomes evident in the ﬁrst months of life. Truncal muscular
hypotonia and weakness of the legs contributes to the delay in
developmental milestones. Signs of cerebellar ataxia, due to a small
cerebellum manifest in early childhood. The cerebellum might be
reported as normal in very young CDG-Ia children, but on serial
imaging it was shown, that the development of the cerebellum was
delayed or even arrested. This is most probably due to abnormal
glycosylation of key factors that play a role in the maturation of the
cerebellum [18,22]. On the other hand the complete loss of the
Purkinje cells and subtotal loss of granule cells throughout the
cerebellar cortex has been seen on autopsies, reﬂecting progressive
degeneration [23]. Cerebellar atrophy has been documented as early
as at the age of 1 month in a neonate with CDG-Ia consistent with
wide variation in the onset of atrophy [24]. Absence of cerebellar
hypoplasia/atrophy does not exclude CDG-Ia [25]. Supratentorial
abnormalities include global atrophy and hydrocephalus [19].
Acquired microcephaly is commonly seen [53].
The majority of older CDG-Ia patients are wheelchair bound. Deep
tendon reﬂexes are usually diminished from an early age and often
cannot be elicited in later life. Accordingly, nerve conduction velocities
are reduced. On nerve biopsies, multivacuolar inclusions of the
Schwann cells were seen [26]. CDG-Ia patients have epilepsy of
various types and usually the seizures can be well controlled.
In late infancy, communication is frequently difﬁcult with dissocia-
tion between comprehension and expression: The level of comprehen-
sion is underestimated because of difﬁculties in expressive language
compounded by dyspraxia and dysarthria. Their intelligence is very
variable, and borderline or normal ability has been reported [9,27–31].
Neurological regression is usually not seen inCDG-Ia,with the exception
of those patients developing secondary neurological sequelae after
stroke-like episodes. The latter can result in sudden unconsciousness,
convulsions, transient blindness or hemiplegia which might be
reversible (in the majority of cases). The aetiology of the stroke-like
episodes is not understood and is most probably multifactorial. In a
patient who had had two stroke episodes, magnetic resonance imaging
(MRI) ﬁndings revealed in one an ischemic stroke, and the other
demonstrated marked oedema followed by focal necrosis [32]. In
another case, after a stroke-like episode, magnetic resonance spectro-
scopy showed a decrease of the N-aspartylaspartate peak, consistent
with neuronal loss [21,33]. Episodes of stupor and coma might be
triggered by infections or strokes (personal observation).
Individuals with CDG-Ia are usually very social, of warm character
and extroverted.3.2. Gastrointestinal tract and liver
Failure to thrive is a very common feature of CDG-Ia and the
majority of patients will beneﬁt from nasogastric or gastrostomy
feedings especially in the early years. Many patients have been
investigated for malabsorption with usually negative results. Protein-
loosing enteropathy may contribute to low albumin concentrations
[34] and renal tubular acidosis, nephritic syndrome and/or tubulo-
pathy might aggravate the failure to thrive. Hepatopathy with
recurrent increased plasma transaminases and hepatomegaly are
particularly seen during intercurrent illnesses. On liver biopsy,
steatosis, ﬁbrosis and enlargement of the portal tracts has been
reported [34]. We have previously shown lysosomal inclusions that
spare Kupffer cells [35]. CDG-Ia patients have died in liver failure and
autopsy showed micronodular cirrhosis and lamellar inclusions in the
lysosomes of the hepatocytes [35,36].
3.3. Kidney
There are only limited reports on kidney abnormalities in CDG-Ia,
however bilateral hyperechoic kidneys are often seen on ultrasound
[37]. Enlarged kidneys [38], renal cysts [39] and microcystic renal
changes with congenital nephrotic syndrome of diffuse mesangial
sclerosis type have been reported [25,36,40]. It is thought, that the
microcystic changes of the renal parenchyma of neonatal onset, might
be due to ciliary dysfunction secondary to alteration of tubular
glycoproteins [37]. Even though, these changes are commonly seen in
CDG-Ia, the renal function seems to be well preserved in the long term
(personal observation).
3.4. Heart
In 1992, Clayton et al. described hypertrophic obstructive cardio-
myopathy as a new feature in CDG-Ia [41]. Since then several CDG-Ia
patients, usually at young age, have been reported with (hypertrophic
or dilative) cardiomyopathy, pericardial effusions or even myocardial
infarct and cardiac tamponade [24,42–45]. Treatment of the peri-
cardial effusions might be difﬁcult and diuretics, albumin infusions
or corticosteroids have been given, in some cases followed by
pericardial-pleural shunting [46].
3.5. Eyes
Roving eye movements and squint is often seen in very young
CDG-Ia children. They have deﬁcient eye abduction but interestingly,
the squint often corrects itself, so that any early surgical intervention
should be avoided. Visual maturation in CDG-Ia may be delayed and
progressive myopia has also been described [47]. Retinitis pigmen-
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predominantly seen in older CDG-Ia patients [48–50]. Despite
progressive deterioration of the electroretinogram (ERG), central
vision may be preserved [51]. Transient blindness may occur after
suffering from a metabolic stroke but there is a chance for full
recovery (personal observations).
3.6. Endocrine system
CDG-Ia patients usually have normal fetal growth. A study of 25
Danish CDG-Ia patients with the same genotype (R141H/F119L)
documented immediate postnatal onset of growth failure with a
decline in weight and length from early on with no prepubertal catch
up [52]. The cause of the faltering growth is not well understood and is
likely to be multifactorial.
In CDG-Ia free serum thyroxin is typically decreased, with
increased thyroid-stimulating hormone but decreased thyroxin bind-
ing globulin. Generally, hypergonadotropic hypogonadism occurs in
females. Levels for GH, FSH and prolactin ﬂuctuate [54].
Persistent hyperinsulinaemic hypoglycaemia in CDG-Ia has
been shown to be diazoxide responsive, as in patients with CDG-Ib
[55]. Histology of the pancreas showed no focal abnormalities
[56,57].
3.7. Skeletal system
Typically, CDG-Ia patients have long fusiform phalanges of the
ﬁngers. Large limb joints can be restricted, contrasting with the
muscular hypotonia but consistent with reduced movements
in utero.
Various deformities including kyphosis, kyphoscoliosis and
chest deformities may develop in young teenagers. Progressive
paresis caused by spinal cord compression due to atlantoaxial sub-
luxation is a rare but serious complication in patients with CDG-Ia
[59]. Osteopenia, revealed on skeletal radiography and den-
sidometry, may need early treatment [14,16,60]. A recent review
by Coman et al. lists the diverse range of skeletal abnormalities
in CDG patients [58] including “dysostosis multiplex-like pheno-
type” [61] and the radiological changes reminiscent of type II
collagenopathy [62].
3.8. Skin and hair
Abnormal distribution of subcutaneous fat, or tough (“peau
d'orange”) or puffy skin and subcutaneous tissue, is usually present
at birth. Often lipodystrophy is seen on the buttocks, which might
disappear with time. Silengo et al. described hair abnormalities in
CDG-Ia, being sparse and course textured, lacked lustre, growing
slowly. Microscopically, trichorrhexis nodosa and pili torti was seen
[63].
4. Dysmorphic features
CDG-Ia patients have rather subtle facial dysmorphism; in
particular large somewhat dysplastic ears, high forehead, triangular
face and thin upper lip [64]. Commonly seen, however not diagnostic,
is the presence of inverted nipples, which might be displaced laterally
and can normalise with age. Abnormal fat distribution may be
localised or generalised.
5. Mortality in CDG-Ia
It is estimated, that about 20% of CDG-Ia patients die in the ﬁrst
years of life, particularly those, who present with the “visceral” form
[64]. Sudden death may occur at older age, despite patients having
apparently been very stable (personal observation).6. Neonatal onset
Although CDG-Ia patients are usually born after an uneventful
pregnancy with good birth weight, several cases of hydrops fetalis
have been reported [65,66]. Pericardial ﬂuid accumulation and ascites
were also observed in a few young patients with CDG type Ia,
developing life-threatening extravascular ﬂuid accumulation as
reported by Truin et al. in three children: one patient was successfully
treated with a pericardial-pleural shunt. Pericardial ﬂuid accumula-
tion and generalised oedema resolved temporarily in the other two
children on regular albumin infusions and the use of diuretics.
However, in one of those children, severe extravascular ﬂuid
accumulation subsequently progressed leading to decompensation
and death. The abdominal ﬂuid and pericardial ﬂuid have a high
extracellular protein concentration and increased cytokine concentra-
tions, consistent with a local activation of the cytokine pathways and
subsequent protein transport through the endothelial surface to the
extravascular space [46].
Another CDG-Ia baby presented early with hypertrophic non-
obstructive cardiomyopathy with marked peripheral oedema.
Although hydrops fetalis was suspected it was not conﬁrmed as
there was no ascites and pleural effusions. In another case, the most
striking clinical problems were therapy-resistant arterial hyperten-
sion and recurrent pericardial and pleural effusions. Persistent
congenital thrombocytopenia, hyperferritinaemia activated macro-
phages were noted [67].
A very rare condition called mirror syndrome (fetal hydrops with
subsequent oedema in the pregnant woman) has been reported in a
woman in two pregnancies complicated by this syndrome. Congenital
disorder of glycosylation type Ia (CDG-Ia) was identiﬁed as the
underlying disease in the foetus in both cases [68].
7. CDG-Ia in adulthood
There is still scant recognition of adults with CDG-Ia. In
adolescence and adulthood, the condition appears to be static without
-regression. Patients have moderate mental retardation, ataxia,
retinitis pigmentosa, peripheral neuropathy, kyphoscoliosis, and
endocrinopathies. Adult female CDG-Ia patients have signs of
hypogonadism, whereas male patients appear to have a normal
puberty. They may have decreased testicular volume and testicular
atrophy [54,69]. Skeletal problems include signiﬁcant kyphoscoliosis,
joint contractures, and osteopenia. Muscle wasting seems to be
secondary to progressive neuropathy. As in childhood, the severity of
the disease is broad but the majority of CDG-Ia adults will not be
independent [14,16,70,71].
8. Differential diagnosis
As CDG-Ia has such a variable phenotype, it is not surprising,
that it can mimic other (metabolic) diseases suchlike peroxisomal
or mitochondrial disorders. Clinical overlap has been reported with
two patients with a classical symptoms of MELAS (mitochondrial
encephalopathy, lactic acidosis and stroke like episodes) and in
another patient thought to have NARP (neuropathy, ataxia and
retinitis pigmentosa). All three patients were later diagnosed as
CDG-Ia [72]. Clinical overlap can be seen with Joubert syndrome
[73], pontocerebellar hypoplasia type I–VI, Hoyeraal–Hreidarsson
syndrome, X-linked mental retardation with cerebellar hypoplasia
and distinctive facial appearance syndrome, Arima and COACH
syndrome.
9. Biochemical features
In CDG-Ia, large numbers of serum glycoproteins are abnormally
glycosylated, have reduced concentrations or activities. The
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tion and thrombotic factors, lysosomal enzymes and enzyme
inhibitors.
In the vastmajority of CDG-Ia patients, ATIII, protein C and S are low
with abnormal levels of factors VIII, IX, XI and XIII. This dysequilibrium
betweenprothrombotic and antithrombotic factorsmean an increased
risk for bleeding and thrombosis. Abnormal glycosylation of platelet
glycoproteins in CDG Ia enhance nonspeciﬁc platelet interactions
[74,75]. Arnouxet al. correlated themarked haemostasis abnormalities
of CDG-Ia and acute vascular events to determine risk factors. Acute
vascular events occurred in patients under 15 years of age, especially
with fever and prolonged immobilization [76].
Adult female patients have hypergonadotropic hypogonadismwith
elevation of luteinising hormone and follicle-stimulating hormone. In
themajority of cases, there is absence of puberty with primary ovarian
failure [18]. Elevated liver transaminases are frequently seen during
intercurrent infection, but may be normal when well.
Lysosomal enzymes are frequently elevated in serum, but low in
leukocytes, probably because of insufﬁcient uptake [77]. The mea-
surement of plasma aspartylglucosaminidase has been proven to be an
useful additional marker for CDG-I [78]. Compared to normal controls,
CDG-Ia ﬁbroblasts contain an increased amount of total glyco-
sphingolipids (GSLs) and slower degradation of GLSs, which suggest
that the cell metabolic machinery may be able to partially re-
equilibrate protein hypoglycosylation with increased biosynthesis of
glycosphingolipids [79].
In cerebrospinal ﬂuid hypoglycosylated isoforms of beta-trace
protein, a brain derived glycoprotein was shown, conﬁrming the
presence of hypoglycosylation in the central nervous system [80].
As there is an increased morbidity in young CDG-Ia patients
suffering from severe infections [81], it was thought, that the
glycosylation defect might have an effect on immunoglobulin levels
of patients, however that has not been conﬁrmed [82]. Examination of
membranous glycoconjugates of lymphocytes showed distinct devia-
tions of surface-expressed lactosamoniglycan structures. It was
speculated, that diminished expression of CD22 ligands may have
implications for the maturation process of B lymphocytes [83]. Poor
vaccine response has been reported in two CDG-Ia patients [84].
10. Diagnosis
10.1. Analysis of hypoglycosylated transferrin
Themost commonly used screening test for congenital disorders of
N-glycosylation is still the isoelectric focusing (IEF) of transferrin.
Glycoforms of transferrin or other N-glycoproteins can be separated
and visualised by IEF or by Western blotting/immunoprecipitation
[85]. The predominant glycoform of transferrin contains four
oligosaccharide branches (tetrasialotransferrin) on two N-linked
glycans. Hypoglycosylation of transferrin results in partial deﬁciency
of the terminal, negatively charged sialic acid, and hence in a cathodal
shift. In patients with CDG-I, there is an increase of the a- and
disialotransferrin glycoform and reduction of tetrasialotransferrin. IEF
of transferrin can differentiate between CDG-I (due to defects in the
assembly of dolichol-lipid linked oligosacharides) and CDG-II pattern,
the latter observed in N-glycoprotein trimming and processing
defects. A false positive IEF pattern may be seen in secondary
disorders of glycosylation as in untreated galactosaemia, hereditary
fructose intolerance, haemolytic–uraemic syndrome or alcohol abuse
[86–88]. Amino acid polymorphisms of transferrin can also alter the
IEF pattern. Protein variants in a CDG-suspected individual can be
excluded by performing IEF of the parenteral blood and/or prediges-
tion of the blood samples with neuraminidase [89].
The IEF pattern in patients with CDG-Ia patients may vary with age
and can become less obvious [90]. Normal IEF pattern has been
reported in a few CDG cases with enzymatically and geneticallyproven CDG-Ia [90,91]. It is important to note that IEF of transferrin
has been shown to be unreliable in premature babies and neonates in
the ﬁrst weeks of life, as false negative results have been observed
[92,93].
Quantitative determination of carbohydrate-deﬁcient-transferrin
(CDT) is an alternative method to detect abnormal ratios of di-, mono-
and asialotransferrin [94]. Enzyme-EIA and radioimmunoassay (RIA)
have also been used for screening. To increase sample throughput,
semi-automated methods such like HPLC and capillary electrophor-
esis (CE) are used for CDG screening [95–97]. SELDI-TOF-MS of
transferrin immunocaptured on protein chip array has been proven to
be a highly sensitive, a method that potentially could be fully
automated [98].
Any positive screening test for CDG needs to be followed by
enzymatic and/or molecular genetic testing to conﬁrm the speciﬁc
subtype as various CDG subtypes have been identiﬁed so far. In all
patients with a CDG-I pattern, PMM deﬁciency, the most common
subtype, and phosphomannose isomerase deﬁciency (CDG-Ib, a
treatable CDG subform) should be excluded promptly by enzyme
assays and/or mutational analysis.
10.2. PMM enzyme activity in ﬁbroblasts and leukocytes
PMM is a cytosolic enzyme and converts Mannose 6-phosphate to
Mannose 1-Phosphate in the presence of its cofactor mannose 1,6
biphosphatase or glucose 1,6 biphosphatase, phosphorylating the
catalytic side of PMM. Mannose 1-phosphate is the precursor of
guanosin diphosphomannose (GDP-mannose) [99]. This nucleotide
sugar subsequently donates mannose that is to be attached to the
dolichol-pyrophosphate at the cytosolic membrane of the endoplas-
matic reticulum (ER). Two N-acetylglucosamines (GlcNAc2) and ﬁve
mannoses (Man5) are then added to the lipid-linked oligosaccharide
(LLO) precursor which is then ﬂipped to the luminal side of the ER,
ﬁnally to be assembled to Dol-pyrophosphate-GlcNAc2-Man9-Glc3.
This branched oligosaccharide structure is then linked to the
asparagine residue of the polypeptide to be further processed in the
Golgi apparatus.
PMM deﬁciency responsible for CDG-Ia was established in 1995. Low
PMM activity can be detected in ﬁbroblasts, leucocytes, amniocytes and/
or liver tissueofpatients asdescribedbyvanSchaftingenet al. [2]. It results
in a depletion of the mannose-1-P and hence GDP-mannose pool
[100,101]. Fibroblasts however do not accumulate mannose-6-phosphate
and it has been suggested, that phosphomannose isomerase, the enzyme
acting just upstream of PMM maintains an equilibrium between
mannose-6-P and fructose-6-P [100].
To conﬁrm the diagnosis the measurement of PMM activity in
leucocytes is preferable, as enzyme levels in ﬁbroblasts of genetically
conﬁrmed CDG-Ia patients, overlap with control values [102].
However the PMM leucocyte activity of those with mild PMM2
mutations may still overlap with carrier activities [103].
There are two isoenzymes of PMM – PMM1 and PMM2 – that share
66% sequence homology. Although both isoenzymes catalyse the same
reaction, PMM2 is much more substrate-speciﬁc [104] and its tissue
distribution is different [105]. The role of PMM1 still needs to be
elucidated.
10.3. Mutational analysis
The identiﬁcation of the gene responsible for CDG-Ia was
complicated by the presence of the similarity of two genes, PMM2
and a pseudogene, so called PMM1. It is now known that mutations in
PMM2 are responsible for CDG1a. The incidence for CDG-Ia has been
reported as 1: 20 000 [106,107]. CDG-Ia is certainly still under-
diagnosed [108].
The PMM2 gene, is located on chromosome 16p13. and has 8
exons, a reading frame of 738 base pairs encoding for a protein of 246
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mutations in CDG-Ia patients. There aremutational hot spots in exon 5
and 8. Missense, single or multiple base pair deletions, splice and
nonsense mutations have all been reported [8,106,109–112]. The most
prevalent mutation is R141H with the frequency of carriers as high as
1:72 [107] but so far no homozygote patient has been identiﬁed. This
implies that the homozygous state is likely to be lethal since, using the
Hardy–Weinberg equilibrium the predicted incidence would be
approximately 1 in 20,000 births.
Certain population have predominant mutations such as Scandi-
navian CDG-Ia patients are usually compound heterozygous for the
R141H/F119L mutations, which is invariably associated with very low
PMM activity and severe clinical phenotype [7,18].
The D65Y mutation for example seems to be conﬁned to the
Portuguese and Spanish CDG-Ia patients [113].
Several mutations have been overexpressed in ﬁbroblasts to study
their catalytic activity, afﬁnity for substrates and stability, differentiat-
ing mutations leading to virtually no activity and others with some
residual activities [114,115].
10.4. Glycan structure analysis
Through structure analysis of lipid-linked oligosaccharide (LLO) or
peptide linked -glycoproteins using metabolic labelling, the changes
of the glycosylation pattern can be illustrated. This method is often
used, once an IEF type I pattern has been proven not to be due to PMM
or PMI deﬁciency [116,117].
11. Prenatal diagnosis
Clayton et al.reported 1993 the failure conﬁrming the diagnosis
of CDG by isoelectric focusing pattern in a newborn (later CDG-Ia
was conﬁrmed) [92], but Edwards et al., obtained cord blood from a
CDG-Ia foetus with non-immune hydrops and abnormalities of
serum transferrin isoelectric focussing (IEF) were seen as early as 27
weeks' gestation [118]. Because of these conﬂicting results, prenatal
diagnosis should be performed by mutational analysis with linkage
analysis using ﬂanking, polymorphic markers that will also detect
contamination of the sample. Enzyme analysis of PMM in amniotic
or chorionic villus cells are usually used in tandem as prenatal test
[108].
Schollen et al. reported a higher recurrence risk in families with
CDG-Ia (closer to 1 in 3) which needs to be considered in the genetic
counselling of CDG-Ia families [119].
12. Treatment
Mannose is taken up into cells by a mannose-speciﬁc transporter
and addingmannose to CDG-Ia patients ﬁbroblasts corrected deﬁcient
mannose incorporation [120,121]. However neither oral nor intrave-
nous mannose supplementation has been proven to be beneﬁcial in
CDG-Ia and no changes of the hypoglycosylation of glycoproteins
could be shown [122,123]. Synthesis of a family of mannose-1-
phospate prodrugs which are promising membrane-permanent
derivates of mannose-1-phosphate [124] is in progress.
The management issues for CDG-Ia patients can be numerous and
include failure to thrive, requiring tube feeding. Motor and speech
delay should be helped with combined health therapy, including
physio-, speech and language and occupational therapy. Recurrent
stroke-like episodes can successfully be prevented with low dose
aspirin. The use of anticoagulans however needs to be carefully
considered and individually tailored to the risk proﬁle of each patient.
Coagulation abnormalities in CDG-Ia can result in thrombosis or
bleeding, so acetylsalicylic acid prophylaxis may have an increased
risk for CDG-Ia patients and should be avoided in patients who already
have had any bleeding complications [32,76]. Arnoux et al. recentlypublished a study on the risk assessment of vascular events in CDG-Ia
patients and identiﬁed risk factors for vascular events looking
speciﬁcally on level of factor VIII and IX [76].
Osteopenia may require treatment with biphosphonates [125].
Some CDG-Ia children will need thyroxin supplementation for
hypothyroidism due to low TBG levels. Commonly, female CDG-Ia
patients will need hormonal replacement therapy (HRT). The type of
HRT needs to be carefully chosen because of the increased risk of
thrombembolic complications in CDG-Ia, due to ATIII, protein C and/
or S deﬁciency.
Very recently, a possible role of the use of antisense morpholino
oligonucleotides (AMO) in CDG patients with splicing mutations in
the PMM2 gene has been discussed. Using targeted AMO blocking the
access of the spliceosome machinery resulted in correctly spliced
mRNA (Vega A, communication at SSIEM, 2008).
13. Mouse model
Complete absence of PMM, as in the PMM knock-out mouse
model and the F141H double knock-out leads to very early embryo-
nic death [126]. Compound heterozygote F119L/F141H mouse
embryos only developed to day 9.5. Mating the heterozygous
Pmm2-deﬁcient mice with wild type mice revealed maternal trans-
mission of the Pmm2 null allele being severely impaired [61,126].
The homozygous F119L/F119L knock-out mouse however is viable
and shows a broad spectrum of phenotypes (early embryonic
death to normal phenotype) (Schneider et al., communication
SSIEM 2008).
14. Discussion
Since the last review on CDG-Ia in this journal had been published
nearly ten years ago [127], we have realised, that the clinical
spectrum of CDG-Ia is much broader. This is primarily as a result of
extended screening. The differential diagnosis of congenital disorders
of glycosylation should be considered in any child presenting with
unexplained symptoms. In particular the presence of features such as
inverted nipples, abnormal subcutaneous fat distribution and
cerebellar atrophy should trigger enzymatic or molecular genetic
tests for PMM deﬁciency. As CDG-Ia can present with involvement of
any organ system at any age and with variable degree of severity and
is the most commonest CDG subtype, PMM deﬁciency should be
ruled out in any positive CDG-I screening test by enzyme and/or
mutational analysis.
There is still the need to explain the effect of hypoglycosylation
resulting in such a plethora of symptoms seen in CDG-Ia. The
ongoing mouse models are of utmost importance in helping to
unravel the pathogenesis of CDG-Ia. With increased understanding
of the impact of glycosylation on stability, targeting and clearance of
bioactive molecules hopefully new ideas of effective treatment will
be developed.
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